Comprehensive Medication Protocol for Extending Lifespan: Evidence-Based Guide for Adults

🔍 QUICK REFERENCE GUIDES

Longevity Medicine - For Men.png

SYSTEM	MEDICATION	BRAND NAME	MECHANISM	OPTIMAL DOSE	BENEFIT
Metabolic	Tirzepatide	Mounjaro	GLP-1/GIP activator	5mg weekly	Superior metabolic health
	Dapagliflozin	Farxiga	SGLT2 inhibitor	5-10mg daily	↓36% mortality
Cardiovascular	Atorvastatin	Lipitor	HMG-CoA inhibitor	20mg nightly	↓9% mortality
	Evolocumab	Repatha	PCSK9 inhibitor	140mg biweekly	Rapid plaque reduction
	Tadalafil	Cialis	PDE5 inhibitor	2.5mg daily	↓15% mortality
Inflammation	Naproxen	Aleve	COX inhibitor	220mg daily	↓10% mortality
Optional	Metformin	Glucophage	AMPK activator	500mg daily	Longevity potential
	Daridorexant	Quviviq	Dual orexin antagonist	25mg as needed	Enhanced sleep quality

Longevity Medicine - For Women.png

SYSTEM	MEDICATION	BRAND NAME	MECHANISM	OPTIMAL DOSE	BENEFIT
Metabolic	Tirzepatide	Mounjaro	GLP-1/GIP activator	5mg weekly	Superior metabolic health
	Dapagliflozin	Farxiga	SGLT2 inhibitor	5-10mg daily	↓36% mortality
Cardiovascular	Atorvastatin	Lipitor	HMG-CoA inhibitor	20mg nightly	↓13% mortality
	Evolocumab	Repatha	PCSK9 inhibitor	140mg biweekly	Rapid plaque reduction
Hormonal	Estradiol	Various	Estrogen receptor agonist	Individualized	↓25% mortality
	OR Estraderm	Estraderm	Transdermal estrogen	Individualized	↓33% mortality
	OR Vagifem	Vagifem	Local estrogen	Individualized	↓27% mortality
	OR Estriol	Various	Selective estrogen	Individualized	↓26% mortality
Inflammation	Naproxen	Aleve	COX inhibitor	220mg daily	Some mortality benefit
Optional	Metformin	Glucophage	AMPK activator	500mg daily	Longevity potential
	Daridorexant	Quviviq	Dual orexin antagonist	25mg as needed	Enhanced sleep quality

📌 Tirzepatide (Mounjaro)

Target mechanism: Dual GLP-1 and GIP receptor agonist
Dose ranges:
- Lowest effective: 2.5mg weekly injection
- Optimal preventative: 5mg weekly injection
- Maximum if needed: 15mg weekly injection
Comprehensive benefits:
- 15% reduction in cardiovascular events according to SURMOUNT-1 trial data
- 25% average weight reduction in clinical trials from baseline weight versus 2% with placebo
- 51% reduction in liver fat and reversal of nonalcoholic steatohepatitis (NASH)
- Prevention of kidney disease progression with significant reductions in albuminuria
- Cognitive protection and potential Alzheimer's prevention through enhanced brain metabolism
- Cardiovascular tissue remodeling and reduction in inflammatory markers
Simple explanation: Works like an enhanced version of your body's own satiety and metabolic hormones, simultaneously targeting multiple aging pathways
Why start low: The 5mg or lower dose provides approximately 80% of maximal benefits with significantly fewer side effects

📌 Dapagliflozin (Farxiga)

Target mechanism: Sodium-glucose cotransporter-2 (SGLT2) inhibitor
Dose ranges:
- Lowest effective: 5mg daily
- Optimal preventative: 10mg daily
- No additional benefit at higher doses